The inactivated vaccine developed by Sinopharm's China National Biotec Group (CNBG) is broad-spectrum and can cross-neutralize different coronavirus strains, said CNBG chairman Yang Xiaoming.

China granted conditional market approval for the vaccine developed by the Beijing Biological Products Institute Co., Ltd. under the CNBG last month.

It showed 79.34 percent efficacy against COVID-19, and the seroconversion rate of neutralizing antibodies reached 99.52 percent, indicated the interim results of the phase-3 clinical trials.